How the immune signal IL-10 controls fat tissue's calorie burning
Interleukin-10 mediated immune cell-adipocyte crosstalk in adipose thermogenesis
Researchers want to learn how the immune molecule IL-10 and immune cells change fat cells' ability to burn energy, with the goal of helping people with obesity or type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11290383 on NIH RePORTER |
What this research studies
The team will block or remove IL-10 signaling in fat and immune cells and measure how that changes fat tissue's ability to become thermogenic (burn energy). They will use genetic mouse models, bone marrow reconstitution to track immune-cell origins, and cellular analyses including chromatin accessibility and mitochondrial function tests. The work aims to identify which immune cells make IL-10 in fat and how IL-10 alters fat cell metabolism and gene activity. Results could point to targets that later lead to treatments that increase healthy calorie burning in people.
Who could benefit from this research
Good fit: The eventual human candidates for therapies based on this research would most likely be adults with obesity, insulin resistance, or type 2 diabetes interested in metabolic treatments.
Not a fit: People without metabolic problems or those expecting immediate personal treatment from this basic laboratory research are unlikely to receive direct benefit from this grant.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost calorie burning in fat to help control obesity and improve blood sugar control in people with metabolic disease.
How similar studies have performed: Prior animal studies, including the investigators' earlier work, showed that removing IL-10 signaling in mice can improve glucose control and promote 'browning' of fat, but translating these findings to human treatments remains unproven.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Rajbhandari, Prashant — Icahn School of Medicine at Mount Sinai
- Study coordinator: Rajbhandari, Prashant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.